ライフサイエンスコーパス: antiseizure

1 hese studies propose a new mechanism for the antiseizure action of the ketogenic diet.

2 hibition, therefore, could contribute to PMP antiseizure action or the adverse effects that are signi

3 (R)-7 [(R)-AS-1] showed broad-spectrum antiseizure activity across in vivo mouse seizure models

4 nnabinoid constituent of cannabis, has shown antiseizure activity and behavioral benefits in preclini

5 A remarkable separation between antiseizure activity and CNS-related adverse effects was

6 Levetiracetam was discovered to have antiseizure activity in animal models and was then found

7 Fenfluramine has been reported to have antiseizure activity in observational studies of photose

8 potent adenosine kinase (AK) inhibitors with antiseizure activity in the rat maximum electroshock (ME

9 tones beta-hydroxybutryate or acetone, shows antiseizure activity in two acute ex vivo rat hippocampa

10 iform activity and significantly blocked the antiseizure activity of AP in the kindling model of epil

11 The antiseizure activity of benzodiazepines (BDZs) 1-5 in mi

12 Finasteride reversed the antiseizure activity of DOC (ED50, 7.2 mg/kg); partial a

13 om), compatible with a role for DHDOC in the antiseizure activity of DOC.

14 Separate from its antiseizure activity, dilantin interferes with microtubu

15 Lacosamide is an antiseizure agent that targets voltage-dependent sodium

16 inhibitory neurotransmitter and an important antiseizure agent.

17 nosine kinase inhibitors (AKIs) as potential antiseizure agents and demonstrated an adenosine recepto

18 nge of applications, including screening for antiseizure agents and identifying channel blockers of i

19 ctivated states in a manner similar to other antiseizure agents but with slower kinetics of binding a

20 autoimmune disorders is needed to guide new antiseizure and anti-epileptogenic treatments.

21 brain and the MMP inhibitor IPR-179 exhibits antiseizure and antiepileptogenic effects in rodent epil

22 ns of TBI, seizures, and medications such as antiseizure and antipsychotics with the progression of c

23 advance the discovery and development of new antiseizure and/or antiepileptogenic therapies.

24 atory findings warrant further assessment of antiseizure approaches in AD.

25 -hormonal drugs, such as antidepressants and antiseizure compounds to alleviate hot flushes.

26 's drug metabolism capacity is important for antiseizure dose personalization.

27 The cause of antiseizure drug (ASD) resistance in epilepsy is poorly

28 ether epileptogenesis enhances synchrony and antiseizure drug administration disrupts it.

29 s indicated by the clinical finding that the antiseizure drug carbamazepine (CBZ) relieves pain becau

30 tchable derivatives of the widely prescribed antiseizure drug carbamazepine.

31 euronal excitability and highlight potential antiseizure drug development strategies based on the Na(

32 2A) is a presynaptic protein targeted by the antiseizure drug levetiracetam.

33 etam; PET imaging tracer UCB-J; experimental antiseizure drug padsevonil; and allosteric modulator UC

34 Perampanel (PMP) is a third-generation antiseizure drug reported to be a potent and selective n

35 The following 4 antiseizure drug strategies were included: (1) conservat

36 CANCE STATEMENT PMP is a regulatory approved antiseizure drug used for refractory partial-onset and g

37 In this study, the effects of the antiseizure drug valproic acid (VPA) on the expression o

38 denoted treatment with 1 or more intravenous antiseizure drug, more than 1 intravenous anesthetic, an

39 Phenobarbital (PB), a broadly used antiseizure drug, was the first to be characterized as a

40 denoted treatment with none or 1 intravenous antiseizure drug.

41 noted treatment with more than 1 intravenous antiseizure drug.

42 Despite the availability of approximately 30 antiseizure drugs (ASDs), epilepsy remains a major unmet

43 seizures while minimizing adverse effects of antiseizure drugs (ASDs).

44 tives and antipsychotic, antidepressant, and antiseizure drugs as well as drugs of abuse, such as coc

45 tients were categorized by administration of antiseizure drugs given during hospitalization.

46 Epilepsy therapy is based on antiseizure drugs that treat the symptom, seizures, rath

47 Plasma concentrations of antiseizure drugs were quantified with the dose-normaliz

48 use of benzodiazepine drugs, phenobarbital, antiseizure drugs, and alpha-2 adrenergic drugs.

49 None of the patients was prescribed antiseizure drugs, either owing to physician recommendat

50 eractions with targets reported for marketed antiseizure drugs, indicative of a novel and unprecedent

51 acterized by seizures that respond poorly to antiseizure drugs, psychomotor delay, and cognitive and

52 les include neuroinhibitory medications like antiseizure drugs, which are used against epilepsy and n

53 30% of focal epilepsies remain resistant to antiseizure drugs, with effective drug development imped

54 ynchrony is modulated by epileptogenesis and antiseizure drugs.

55 sy contributes to seizures and resistance to antiseizure drugs.

56 st in 35% of patients despite optimal use of antiseizure drugs.

57 s fail to become seizure-free in response to antiseizure drugs.

58 cant differences in plasma concentrations of antiseizure drugs.

59 /ED50) that compared favorably with clinical antiseizure drugs.

60 Optogenetic or KCl-induced SDs had similar antiseizure effect sustained for more than 30 min.

61 Low doses of MK801, which had no antiseizure effect, impaired the progression of kindling

62 e that HCAR2 mediates beta-hydroxybutyrate's antiseizure effects by regulating neuronal excitability

63 nse oligonucleotides (antagomirs) had potent antiseizure effects in animal models, whereas genetic de

64 KB alone were sufficient to: (1) exert antiseizure effects in Kcna1-null mice, (2) restore intr

65 of this study was to demonstrate the direct antiseizure effects of KB and to identify an underlying

66 the conversion of DOC to DHDOC, reversed the antiseizure effects of stress.

67 nhibition of TGF-beta signaling occluded the antiseizure effects of the antagomirs.

68 und to mirror and reverse, respectively, the antiseizure effects of the KD in Kcna1-null mice.

69 lution revealed that these ureas exert their antiseizure effects through activation of K(V)7 potassiu

70 anner, and this is sufficient to explain its antiseizure effects.

71 We found that diazepam loses its antiseizure efficacy and conversely exacerbates epilepti

72 tions for epilepsy, of which 24 have similar antiseizure efficacy for focal epilepsy and 9 have simil

73 C2 inhibitor furosemide is nonselective with antiseizure efficacy in slices and in vivo, leading to a

74 and that more selective drugs might maintain antiseizure efficacy while reducing adverse effects.SIGN

75 ML297 revealed that in addition to its known antiseizure efficacy, ML297 decreases anxiety-related be

76 uring fasting or treatment with the high-fat antiseizure ketogenic diet (KD).

77 olism-based treatments such as the high-fat, antiseizure ketogenic diet have become mainstream, and m

78 tion of children who had not been exposed to antiseizure medication (4,199,796 children).

79 , the incidence was 4.2% with no exposure to antiseizure medication (8815 children), 6.2% with exposu

80 Prenatal antiseizure medication (ASM) exposure has been associate

81 re is little evidence to guide the choice of antiseizure medication (ASM) for patients with poststrok

82 Antiseizure medication (ASM) may interact with folate me

83 Women with epilepsy frequently need antiseizure medication (ASM) to prevent seizures in preg

84 Antiseizure medication (ASM) treatment duration for acut

85 Prenatal exposure to antiseizure medication (ASM), defined as any maternal pr

86 at or before the index date or dispensed an antiseizure medication 12 months before or 90 days after

87 tions, as a substantial portion of available antiseizure medication act by enhancing GABAergic functi

88 mproved consciousness and without additional antiseizure medication at 1 h from start of drug infusio

89 children were seizure-free, and 44% stopped antiseizure medication at a 5.1-year mean follow-up (ran

90 core differences were seen in children using antiseizure medication at time of testing (e.g. valproat

91 epsy diagnosis and a filled prescription for antiseizure medication between 1 January 2009 and 31 Dec

92 ding seizure freedom and the opportunity for antiseizure medication cessation, epilepsy surgery might

93 High-antiseizure medication cost centers had higher odds of d

94 ds of death or NDI yet higher laboratory and antiseizure medication costs were not.

95 cy were compared with those unexposed to any antiseizure medication during pregnancy with respect to

96 However, some exposure-dependent antiseizure medication effects were seen in secondary an

97 minority, lack of counselling, young age, no antiseizure medication exposure and concerns about its u

98 For Verbal Index scores, antiseizure medication exposure effects were not seen fo

99 either a classic ketogenic diet or a further antiseizure medication for 8 weeks.

100 ndings should be considered when choosing an antiseizure medication for a person at risk for cardiova

101 ic and periodic EEG activity with the use of antiseizure medication for at least 48 hours plus standa

102 the ketogenic diet group (5 [IQR 1-16]) and antiseizure medication group (3 [IQR 2-11]; IRR 1.33, 95

103 group and 26 [45%] of 58 participants in the antiseizure medication group).

104 ts apo form and in complex with FDA-approved antiseizure medication levetiracetam; PET imaging tracer

105 Antiseizure medication might suppress seizures in up to

106 Every antiseizure medication needs to be assessed individually

107 are frequently refractory to the first-line antiseizure medication phenobarbital.

108 induced gingival overgrowth is caused by the antiseizure medication phenytoin, calcium channel blocke

109 The antiseizure medication primidone, a known TRPM3 antagoni

110 lepsy specialist who can also optimize their antiseizure medication regimen before and during pregnan

111 m seizure-freedom was highest with the first antiseizure medication regimen, at approximately 50%.

112 based on current seizure state and number of antiseizure medication regimens trialled.

113 on both current seizure state and number of antiseizure medication regimens trialled.

114 The relative contribution of antiseizure medication to cortical thickness is unknown.

115 may inform decisions on the continuation of antiseizure medication treatment and the methods and fre

116 Children who had discontinued antiseizure medication treatment at 1-year follow-up sho

117 lex set of circumstances, safe and effective antiseizure medication treatment, evidence-based decisio

118 iveness of contraceptives can be modified by antiseizure medication treatments and pregnancy can alte

119 ng on stimulated hemisphere, block order, or antiseizure medication use, but was greater in older chi

120 Patients with a history of seizure, antiseizure medication use, or renal failure requiring d

121 ion with Epstein-Barr virus responded to the antiseizure medication valproate with entry into the lyt

122 d ratios in a comparison with no exposure to antiseizure medication were 0.96 (95% confidence interva

123 0.9-2.8), time from surgery to the start of antiseizure medication withdrawal (aHR 0.9, 95% CI 0.8-0

124 models may assist clinicians when discussing antiseizure medication withdrawal after surgery with the

125 zure recurrence after starting postoperative antiseizure medication withdrawal and develop and valida

126 We included 850 adults who started antiseizure medication withdrawal following resective ep

127 motor aware seizures, following the start of antiseizure medication withdrawal were focal non-motor a

128 cal non-motor aware seizures before starting antiseizure medication withdrawal.

129 eizure outcomes after starting postoperative antiseizure medication withdrawal.

130 lists, decreased access and longer waits for antiseizure medication, and increased prescriptions for

131 er in efficacy and tolerability to a further antiseizure medication, and it appears to be safe to use

132 ic could be considered as adjunct therapy to antiseizure medication, as it might reduce fatal complic

133 were assigned to a ketogenic diet and 58 to antiseizure medication, of whom 61 and 47, respectively,

134 ine and may aid in decision-making regarding antiseizure medication, patient counseling, and facilita

135 to a benzodiazepine and at least 1 standard antiseizure medication, treated with continuously infuse

136 identified HLA-B*15:02 carriers had suffered antiseizure medication-induced cADRs; the point prevalen

137 for pharmacogenomic risk factors related to antiseizure medication-induced cutaneous adverse drug re

138 d, regardless of whether switched to another antiseizure medication.

139 within a 48-hour window, and under the same antiseizure medication.

140 r outcomes was increased with greater use of antiseizure medication.

141 en who were seizure free and still receiving antiseizure medication.

142 shift in SE management with increased use of antiseizure medications ( p = 0.007) after ICU-electroen

143 Open-label trials of antiseizure medications (ASMs) and devices suggest seizu

144 s despite treatment with currently available antiseizure medications (ASMs) and may benefit from nove

145 Antiseizure medications (ASMs) are frequently prescribed

146 Antiseizure medications (ASMs) are potential teratogens

147 Antiseizure medications (ASMs) are the mainstay of treat

148 Most antiseizure medications (ASMs) carry a US Food and Drug

149 gulants (DOACs) are commonly prescribed with antiseizure medications (ASMs) due to concurrency of and

150 ence regarding the long-term safety of other antiseizure medications (ASMs) during pregnancy remains

151 n with epilepsy (WWE) require treatment with antiseizure medications (ASMs) during pregnancy, which m

152 Antiseizure medications (ASMs) during the first trimeste

153 Epilepsy was defined as use of 1 or more antiseizure medications (ASMs) for 30 days or longer wit

154 potential role of genetic predisposition and antiseizure medications (ASMs) in any associations obser

155 ting seizure response and drug resistance to antiseizure medications (ASMs) in people with focal epil

156 Use of valproate and certain other antiseizure medications (ASMs) in pregnancy is associate

157 However, the effectiveness of antiseizure medications (ASMs) in preventing epilepsy in

158 the comparative effectiveness of alternative antiseizure medications (ASMs) in these patients.

159 y was undertaken to determine the effects of antiseizure medications (ASMs) on multidien (multiday) c

160 The association of fetal exposure to antiseizure medications (ASMs) with outcomes in childhoo

161 g interictal epileptiform discharges (IEDs), antiseizure medications (ASMs), and intermittent periods

162 ts, epilepsy cannot be controlled by current antiseizure medications (ASMs).

163 sks of fetal exposure are uncertain for many antiseizure medications (ASMs).

164 ivaracetam (BRV) and levetiracetam (LEV) are antiseizure medications (ASMs); UCB-J is a PET tracer ta

165 Enzyme-inducing antiseizure medications (eiASMs) have been hypothesized

166 Both epilepsy and enzyme-inducing antiseizure medications (eiASMs) having varying reports

167 The use of antiseizure medications (HR, 1.23; 95% CI, 0.99-1.53), a

168 91; 95% CI, 2.22-3.81; P < .001), and use of antiseizure medications (RR = 2.44; 95% CI, 1.98-3.02; P

169 Antiseizure medications act primarily on neurons and can

170 All available antiseizure medications aim at symptomatic control of ep

171 tator superfamily (MFS), is a key target for antiseizure medications and a biomarker for synaptic den

172 Antiseizure medications and responsive neurostimulation,

173 Traditional antiseizure medications and the ketogenic diet remain th

174 One limiting factor in the success of antiseizure medications are challenges in mapping the ne

175 Currently available antiseizure medications are effective in around two-thir

176 elopmental effects of fetal exposure to most antiseizure medications are unclear.

177 Current antiseizure medications are unsatisfactory, as they mere

178 be weighed against potential acute risks of antiseizure medications as well as the risk of inappropr

179 awal (aHR 0.9, 95% CI 0.8-0.9) and number of antiseizure medications at time of surgery (aHR 1.2, 95%

180 dition may remain refractory to conventional antiseizure medications but may respond to immunotherapy

181 with epilepsy, lower blood concentrations of antiseizure medications can have adverse clinical conseq

182 nt with a clinically relevant combination of antiseizure medications can have long-lasting effects on

183 etween children with fetal exposure to newer antiseizure medications compared with unexposed children

184 Furthermore, although treatment with some antiseizure medications convey lifelong risks to offspri

185 Use of antiseizure medications for early seizure prophylaxis af

186 After two appropriately used antiseizure medications have failed to control seizures,

187 Although most studies of other antiseizure medications have not shown increased risks o

188 Although second-generation antiseizure medications have not substantially reduced t

189 Since 1989, 18 second-generation antiseizure medications have reached the market, resulti

190 Some second-generation antiseizure medications have shown advantages in tolerab

191 e effects of fetal exposure to commonly used antiseizure medications on neuropsychological outcomes a

192 e has been little evidence that conventional antiseizure medications or their combinations are helpfu

193 Exposure of neonatal macaques to the antiseizure medications phenobarbital and midazolam (PbM

194 Antiseizure medications represent the mainstay of epilep

195 to reach strong conclusions about the newest antiseizure medications such as eslicarbazepine, perampa

196 g children prenatally exposed to the studied antiseizure medications than in the general population.

197 ned in a 1:1 ratio to a stepwise strategy of antiseizure medications to suppress this activity for at

198 kely to persist, regardless of the number of antiseizure medications trialled to reach that point.

199 ologic function, with an increased number of antiseizure medications used.

200 Exposure to specific antiseizure medications was defined on the basis of pres

201 Most antiseizure medications were developed in animal models

202 ho were receiving a stable regimen of 1 to 4 antiseizure medications were eligible for this study.

203 increased prescriptions for enzyme-inducing antiseizure medications when compared with non-Indigenou

204 e countries, where access to contraceptives, antiseizure medications with adequate safety profiles, a

205 SMs) are the mainstay of treatment, but many antiseizure medications with variable safety profiles ha

206 e seizures per week and two or more previous antiseizure medications) were recruited from 19 hospital

207 epsy in this population, discuss appropriate antiseizure medications, and evaluate potential surgical

208 ug interactions between cancer therapies and antiseizure medications, and medication side-effects, ca

209 sies, elucidating the mechanistic effects of antiseizure medications, and ultimately, targeting curre

210 with epilepsy who were prenatally exposed to antiseizure medications, but not high-dose folic acid, a

211 First-line treatment options include >20 antiseizure medications, but seizure control is not achi

212 to be more efficacious than first-generation antiseizure medications, highlighting the need for novel

213 susceptibility, poor fortification policies, antiseizure medications, increased demands, chronic infl

214 Besides antiseizure medications, other treatments such as vagal

215 Despite a century of development of antiseizure medications, up to a third of people with ep

216 Moreover, therapeutic doses of the antiseizure medications, valproic acid and levetiracetam

217 tion or elimination include less exposure to antiseizure medications, which may lead to improved deve

218 ked seizures, that are commonly resistant to antiseizure medications.

219 in offspring following paternal exposure to antiseizure medications.

220 izure freedom and might consider withdrawing antiseizure medications.

221 ilepsy receiving a stable regimen of up to 3 antiseizure medications.

222 able and dynamic trajectories in response to antiseizure medications.

223 pregnancy can alter the pharmacokinetics of antiseizure medications.

224 scales, seizure frequency and the number of antiseizure medications.

225 is insufficient to determine the effects of antiseizure medications.

226 risk of congenital anomalies associated with antiseizure medications.

227 seizures despite adequate trials of standard antiseizure medications.

228 zures continue despite previously trying two antiseizure medications.

229 hies, which often fail to respond to classic antiseizure medications.

230 a rat epilepsy model, mice treated with the antiseizure medicine cannabidiol, and plasma from patien

231 cing seizure frequency compared with further antiseizure medicine in infants with drug-resistant epil

232 the prevalence of epilepsy and purchases of antiseizure medicines (ASMs) among patients with FTD, ma

233 n 2 years and adults who are unresponsive to antiseizure medicines.

234 third of patients stopped or decreased their antiseizure medicines.

235 umatic seizure will likely require long-term antiseizure medicines.

236 Antiseizure phenotypes were observed upon knockdown of m

237 ffinity at racetam-binding sites and greater antiseizure potency.

238 Immunosuppressive medications may have antiseizure properties and trigger certain drug interact

239 ice lacking PRs show supersensitivity to the antiseizure responses of progesterone.

240 esis of epilepsy which represent therapeutic antiseizure targets.

241 Holistic management, which encompasses antiseizure therapies and care for multimorbidities, is

242 The need for novel, efficacious, antiseizure therapies is widely acknowledged.

243 dels has led to the development of effective antiseizure therapies that are routinely used in clinica

244 epilepsy duration, neuroimaging findings, or antiseizure treatment between cases and controls.

245 At 3 months, 79 of 88 patients (90%) in the antiseizure-treatment group and 77 of 84 patients (92%)

246 Mortality at 3 months was 80% in the antiseizure-treatment group and 82% in the control group

247 rolled 172 patients, with 88 assigned to the antiseizure-treatment group and 84 to the control group.

248 s occurred in 49 of 88 patients (56%) in the antiseizure-treatment group and in 2 of 83 patients (2%)

249 ical ventilation were slightly longer in the antiseizure-treatment group than in the control group.

250 ast 48 consecutive hours plus standard care (antiseizure-treatment group) or to standard care alone (

251 s and trigger certain drug interactions with antiseizure treatments.

252 test for seizure threshold, and rapidly tune antiseizure treatments.